The Ozempic Paradox
The same week that our drug regulator, Health Canada, approved the first generic version of semaglutide—the active ingredient in weight-loss drug Ozempic—a major medical journal published findings highlighting the medication’s troubling connection to eating disorders.
The Ozempic Paradox Continue Reading











